Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $675.31M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 1.66M
Average 1.66M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +66.5% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +66.5% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
HUTCHMED (China) Limited NASDAQ:HCM | $2.65B | $14.90 | Not rated | 46.2 | -7.43% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -5.09% |
SELLAS Life Sciences Group, Inc. NASDAQ:SLS | $1.59B | $7.86 | Not rated | -47.3 | +877.63% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.38B | $20.03 | Not rated | -13.4 | +18.71% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -26.00% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -45.36% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | -1.18% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -32.93% |
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | $171.74M | $2.14 | Not rated | -1.5 | -85.33% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -55.37% |
Continue the stock analysis
Jump to another research area for this company.